-
Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
Share
PARIS--(BUSINESS WIRE)--Regulatory News:
At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), (“Valerio Therapeutics” or the “Company”) decided to appoint Mr Julien Miara as CEO and Chairman of the Board of Valerio Therapeutics, succeeding Ms Shefali Argawal, effective immediately.
Future evolutions related to the Company’s governance will be announced at a later date.
Contacts
Valerio Therapeutics
Investor Relations
ir@valeriotx.com
France: +33 (0) 1 70 38 33 99
U.S.: +1 617 366 1022
More News From Valerio Therapeutics S.A.
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), ba...
Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). On July 1, 2026, Valerio announced the submission of a binding offer for the Acquisition on the basis of an enterprise value of EUR 30 million....
Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics (“Valerio” or the “Company”), today announces that it has entered into a binding term-sheet with Abivax SA (“Abivax”), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement....